[1]林远龙,刘现亮.无复流现象:从基础到临床[J].心血管病学进展,2016,(1):53-58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
 LIN Yuanlong,LIU Xianliang.From Bench to Bed:No-reflow Phenomenon[J].Advances in Cardiovascular Diseases,2016,(1):53-58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
点击复制

无复流现象:从基础到临床()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年1期
页码:
53-58
栏目:
综述
出版日期:
2016-02-20

文章信息/Info

Title:
From Bench to Bed:No-reflow Phenomenon
作者:
林远龙1刘现亮2
1.滨州医学院附属医院,山东 滨州 256600;
2.山东大学齐鲁医院,山东 济南 250000
Author(s):
LIN Yuanlong1LIU Xianliang2
1.Binzhou Medical University Hospital,Binzhou 256603,Shandong,China;
2.Qilu Hospital of Shandong University,Jinan 250000,Shandong,China
关键词:
急性心肌梗死 无复流 缺血-再灌注损伤 微血管阻塞
Keywords:
Acute myocardial infarction No-reflow Ischemia-reperfusion injury Microvascular obstruction
分类号:
R542.2+2
DOI:
10.16806/j.cnki.issn.1004-3934.2016.01.014
文献标志码:
A
摘要:
积极采取双联抗血小板聚集、抗栓治疗以及再灌注治疗,许多患者在发生ST段抬高型心肌梗死后,仍会发生不良心血管事件,其中部分心血管事件的发生与无复流有关。无复流主要有三个发病机制,即微血管的结构改变、功能改变和血管外压迫。很多危险因素,如缺血区域、缺血时间、高血压、吸烟、血脂异常、糖尿病、炎症等,均与无复流的发生相关。现详细阐述无复流的发病机制、诊断评估方法、危险因素、预防和治疗策略。
Abstract:
Despite active measures, such as double antiplatelet therapy, antithrombotics therapy and reperfusion therapy,adverse cardiovascular events will still occur after ST-segment elevation acute myocardial infarction. Part occurrence of the cardiovascular events is connected with the no-reflow phenomenon.No-reflow has three main pathogenic mechanisms, namely structural or functional change of microvascular and extravascular compression. This review will elaborate into these aspects in great detail.

参考文献/References:

[1] Sutton NR, Gurm HS. Door to balloon time: is there a point that is too short?[J]. Prog Cardiovasc Dis,2015,pii: S0033-0620(15)00080-8.
[2] Yellon DM, Hausenloy DJ. Myocardial reperfusion injury[J]. N Engl J Med,2007,357(11):1121-1135.
[3] Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans[J]. J Am Coll Cardiol,2009,54(4):281-292.
[4] Kurtul A, Murat SN, Yarlioglues M, et al. Increased neutrophil-to-lymphocyte ratio predicts persistent coronary no-flow after wire insertion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Clinics,2015,70(1):34-40.
[5] de Luca G, Suryapranata H, Stone GW, et al. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials[J]. Am Heart J,2007,153(3):343-353.
[6] Harrison RW, Aggarwal A, Ou F, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction[J]. Am J Cardiol,2013,111(2):178-184.
[7] Su H, Ji L, Xing W, et al. Acute hyperglycaemia enhances oxidative stress and aggravates myocardial ischaemia/reperfusion injury:role of thioredoxin-interacting protein[J]. J Cell Mol Med, 2013,17(1):181-191.
[8] Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction[J]. Circ Cardiovasc Interv,2010,3(1):27-33.
[9] Oduncu V, Tanalp AC, Erkol A, et al. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty[J]. Am J Cardiol,2011,107(2):179-185.
[10] Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: predictive role of C-reactive protein[J]. J Am Coll Cardiol,2006,47(5):962-968.
[11] 孙瑶,陈光辉,陈韵岱.SYNTAX 积分及其优缺点[J]. 中华老年心脑血管病杂志,2010(3):275-277.
[12] 王锦纹,陈韵岱,王长华.SYNTAX 评分预测急性ST段抬高型心肌梗死介入后无复流[J]. 心肺血管病杂志,2013,(5):557-560.
[13] Modolo R, Figueiredo VN, Moura FA, et al. Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction[J]. Coron Artery Dis,2015,26:562-566.
[14] Niccoli G, Kharbanda RK, Crea F, et al. No-reflow:again prevention is better than treatment[J]. Eur heart J,2010,31(20):2449-2455.
[15] Butler MJ, Chan W, Taylor AJ, et al. Management of the no-reflow phenomenon[J]. Pharmacol Ther,2011,132(1):72-85.
[16] Ito H. Myocardial contrast echocardiography after myocardial infarction[J]. Curr Cardiol Rep,2012,14(3):350-358.
[17] Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention[J]. N Engl J Med,2008,358(6):557-567.
[18] Kumbhani DJ, Bavry AA, Desai MY, et al. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty:an updated meta-analysis of randomized trials[J]. J Am Coll Cardiol,2013,62(16):1409-1418.
[19] Stone GW, Abizaid A, Silber S, et al.Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent(MGuard)in ST-Segment Elevation Myocardial Infarction: The MASTER Trial[J]. J Am Coll Cardiol,2012,60(19):1975-1984.
[20] Cassese S, Esposito G, Mauro C, et al. MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocarDial infarction pAtieNts-(GUARDIAN)trial: study design and rationale[J]. Catheter Cardiovasc Interv,2012,79(7):1118-1126.
[21] Gracida M, Romaguera R, Jacobi F, et al. The MGuard coronary stent: safety, efficacy, and clinical utility[J]. Vasc Health Risk Manag,2015,11:533-539.
[22] Navarese EP, Buffon A, Andreotti F, et al.Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome:a meta-analysis of randomized trials[J]. Atherosclerosis,2012, 222(1):1-7.
[23] de Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty:a meta-analysis of 8 randomized trials[J]. Atherosclerosis,2012,222(2):426-433.
[24] Song YB, Hahn JY, Gwon HC, et al. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention:a magnetic resonance imaging study[J].Am Heart J, 2012,163(3):500-507.
[25] Akpek M, Sahin O, Sarli B, et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[J]. Angiology,2015,66(6):560-567.
[26] Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome:a systematic review and meta-analysis of randomized controlled trials[J]. Clin Cardiol,2013,36(8):E11-E16.
[27] Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction:the STATIN STEMI trial[J]. JACC Cardiovasc Interv,2010,3(3):332-339.
[28] 苏亚坤. 急诊 PCI 术前高负荷他汀对急性心肌梗死患者介入术中无复流预防及短期心功能的影响[D]. 石家庄:河北医科大学, 2014.
[29] 傅向华, 李伟, 邢坤, 等. 预防性冠脉内应用山莨菪碱对急性下壁心肌梗死行直接经皮冠状动脉介入治疗患者心肌再灌注的保护效应[C].天津:中华医学会第十五次全国心血管病学大会论文汇编, 2013.
[30] Galaup A, Gomez E, Souktani R, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4[J]. Circulation,2012,125(1):140-149.
[31] Min Z, Hongbing Y, Yi C, et al. Suppression of NF-κB reduces myocardial no-reflow[J]. PLoS One,2012,7(10):118-121.

相似文献/References:

[1]刘如晨,综述,徐争鸣,等.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2016,(3):240.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.006]
 LIU Ruchen,XU Zhengming,LI Tianchang.Thrombus Aspiration in the Treatment of Acute ST-segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(1):240.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.006]
[2]赵劲东,综述,董平栓,等.合并多支血管病变的急性ST段抬高型心肌梗死介入术治疗策略的研究进展[J].心血管病学进展,2016,(3):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
 ZHAO Jindong,DONG Pingshuan.Research Progress of Interventional Therapy in Patients with ST-elevation Myocardial Infarction and Multivessel Disease[J].Advances in Cardiovascular Diseases,2016,(1):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
[3]余正春,综述,马小静,等.急性心肌梗死并发心源性休克的治疗进展[J].心血管病学进展,2016,(4):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
 YU Zhengchun,MA Xiaojing.Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(1):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
[4]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
 YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(1):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[5]元洋洋 李波.Selvester QRS评分系统研究进展[J].心血管病学进展,2019,(7):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
 YUAN YangyangLI Bo.Research Progress of Selvester QRS Scoring System[J].Advances in Cardiovascular Diseases,2019,(1):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
[6]翁子骞 于波.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2019,(7):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
 WENG ZiqianYU Bo.Thrombus aspiration in acute ST-segment elevation myocardial infarction[J].Advances in Cardiovascular Diseases,2019,(1):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
[7]林莉 韦铁民.急性心肌梗死后心脏破裂[J].心血管病学进展,2019,(7):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
 LIN LiWEI Tiemin.Post-infarction Cardiac Rupture[J].Advances in Cardiovascular Diseases,2019,(1):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
[8]杨颜瑜,苏星,谭敏,等.炎症指标与急性心肌梗死研究进展[J].心血管病学进展,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
 YANG Yanyu,SU Xing,TAN Min,et al.Relationship Between Inflammation Index and Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(1):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
[9]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
 CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(1):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[10]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
 PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(1):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]

备注/Memo

备注/Memo:
作者简介:林远龙(1988—),在读硕士,主要从事冠心病介入治疗研究。Email:782228781@qq.com
通信作者:刘现亮(1962—),主任医师,博士,主要从事冠心病介入治疗研究。Email:xnklxl@163.com
更新日期/Last Update: 2016-02-20